Profiling signatures of ovarian cancer tumour suppression using 2D-DIGE and 2D-LC-MS/MS with tandem mass tagging

Journal of Proteomics

Volumn 74, Issue 4, 2011, Pages 451-465

  Sinclair, John ^a   Metodieva, Gergana ^a   Dafou, Dimitra ^a   Gayther, Simon A ^a   Timms, John F ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

2D DIGE; 2D LC MS MS; Biomarkers; Mass spectrometry; Ovarian cancer; Proteomic profiling; Tandem mass tagging; Tumour suppression

Indexed keywords

PROTEOME;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CHROMOSOME 18; CONTROLLED STUDY; EPITHELIUM; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HYBRID CELL; IMMUNOBLOTTING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MOUSE; NONHUMAN; OVARY CANCER; PHENOTYPE; PRIORITY JOURNAL; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; TWO DIMENSIONAL GEL ELECTROPHORESIS;

CELL LINE, TUMOR; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; MASS SPECTROMETRY; METABOLOME; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROGNOSIS; PROTEOME; PROTEOMICS; REMISSION INDUCTION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TANDEM MASS SPECTROMETRY; TUMOR MARKERS, BIOLOGICAL; TWO-DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

EID: 79952212659     PISSN: 18743919     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jprot.2010.12.009     Document Type: Article

References (49)

1. IARC. GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide (2002 estimates). 2004. http://www-depiarcfr/.
2. Jacobs I.J., Menon U. Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 2004, 3:355-366.
3. Schwartz P.E. Current diagnosis and treatment modalities for ovarian cancer. Cancer Treat Res 2002, 107:99-118.
4. Bast R.C., Badgwell D., Lu Z., Marquez R., Rosen D., Liu J., et al. New tumor markers: CA125 and beyond. Int J Gynecol Cancer 2005, 15(Suppl 3):274-281.
5. Skates S.J., Horick N., Yu Y., Xu F.J., Berchuck A., Havrilesky L.J., et al. Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol 2004, 22:4059-4066.
6. Ramus S.J., Pharoah P.D., Harrington P., Pye C., Werness B., Bobrow L., et al. BRCA1/2 mutation status influences somatic genetic progression in inherited and sporadic epithelial ovarian cancer cases. Cancer Res 2003, 63:417-423.
7. Dafou D., Ramus S.J., Choi K., Grun B., Trott D.A., Newbold R.F., et al. Chromosomes 6 and 18 induce neoplastic suppression in epithelial ovarian cancer cells. Int J Cancer 2009, 124:1037-1044.
8. Dafou D., Grun B., Sinclair J, Lawrenson K., Benjamin E.C., Hogdall E., et al. Microcell mediated chromosome transfer identifies EPB41L3 as a functional suppressor of epithelial ovarian cancers. Neoplasia 2010, 12. New York, NY.
9. Cao Q., Abeysinghe H., Chow O., Xu J., Kaung H., Fong C., et al. Suppression of tumorigenicity in human ovarian carcinoma cell line SKOV-3 by microcell-mediated transfer of chromosome 11. Cancer Genet Cytogenet 2001, 129:131-137.
10. Gharbi S., Gaffney P., Yang A., Zvelebil M.J., Cramer R., Waterfield M.D., et al. Evaluation of two-dimensional differential gel electrophoresis for proteomic expression analysis of a model breast cancer cell system. Mol Cell Proteomics 2002, 1:91-98.
11. Chan H.L., Gharbi S., Gaffney P.R., Cramer R., Waterfield M.D., Timms J.F. Proteomic analysis of redox- and ErbB2-dependent changes in mammary luminal epithelial cells using cysteine- and lysine-labelling two-dimensional difference gel electrophoresis. Proteomics 2005, 5:2908-2926.
12. J.F. Timms, R. Cramer, S. Camuzeaux, A. Tiss, C. Smith, B. Burford, et al. Peptides generated ex vivo from serum proteins by tumor-specific exopeptidases are not useful biomarkers in ovarian cancer. Clinical Chemistry 2010;56:262-71.
13. A. Tiss, J.F. Timms, C. Smith, D. Devetyarov, A. Gentry-Maharaj, S. Camuzeaux, et al. Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum MALDI-TOF MS profiling. International Journal of Gynecological Cancer 2010;20:1518-24.
14. Oshimura M., Kugoh H., Koi M., Shimizu M., Yamada H., Satoh H., et al. Transfer of a normal human chromosome 11 suppresses tumorigenicity of some but not all tumor cell lines. J Cell Biochem 1990, 42:135-142.
15. Quaye L., Dafou D., Ramus S.J., Song H., Gentry-Maharaj A., Notaridou M., et al. Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. Hum Mol Genet 2009, 18:1869-1878.
16. Weinberg F., Chandel N.S. Reactive oxygen species-dependent signaling regulates cancer. Cell Mol Life Sci 2009, 66:3663-3673.
17. Flatt P.M., Polyak K., Tang L.J., Scatena C.D., Westfall M.D., Rubinstein L.A., et al. p53-dependent expression of PIG3 during proliferation, genotoxic stress, and reversible growth arrest. Cancer Lett 2000, 156:63-72.
18. Porte S., Valencia E., Yakovtseva E.A., Borras E., Shafqat N., Debreczeny J.E., et al. Three-dimensional structure and enzymatic function of proapoptotic human p53-inducible quinone oxidoreductase PIG3. J Biol Chem 2009, 284:17194-17205.
19. Davidson B., Hadar R., Schlossberg A., Sternlicht T., Slipicevic A., Skrede M., et al. Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma. Hum Pathol 2008, 39:87-95.
20. Nagakubo D., Taira T., Kitaura H., Ikeda M., Tamai K., Iguchi-Ariga S.M., et al. DJ-1, a novel oncogene which transforms mouse NIH3T3 cells in cooperation with ras. Biochem Biophys Res Commun 1997, 231:509-513.
21. Taira T., Saito Y., Niki T., Iguchi-Ariga S.M., Takahashi K., Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep 2004, 5:213-218.
22. Kim R.H., Peters M., Jang Y., Shi W., Pintilie M., Fletcher G.C., et al. DJ-1, a novel regulator of the tumor suppressor PTEN. Cancer Cell 2005, 7:263-273.
23. Simaga S., Osmak M., Babic D., Sprem M., Vukelic B., Abramic M. Quantitative biochemical analysis of lactate dehydrogenase in human ovarian tissues: correlation with tumor grade. Int J Gynecol Cancer 2005, 15:438-444.
24. Koukourakis M.I., Kontomanolis E., Giatromanolaki A., Sivridis E., Liberis V. Serum and tissue LDH levels in patients with breast/gynaecological cancer and benign diseases. Gynecol Obstet Investig 2009, 67:162-168.
25. Cheretis C., Dietrich F., Chatzistamou I., Politi K., Angelidou E., Kiaris H., et al. Expression of ERp29, an endoplasmic reticulum secretion factor in basal-cell carcinoma. Am J Dermatopathol 2006, 28:410-412.
26. Mkrtchian S., Baryshev M., Sargsyan E., Chatzistamou I., Volakaki A.A., Chaviaras N., et al. ERp29, an endoplasmic reticulum secretion factor is involved in the growth of breast tumor xenografts. Mol Carcinog 2008, 47:886-892.
27. Wang G., Yang Z.Q., Zhang K. Endoplasmic reticulum stress response in cancer: molecular mechanism and therapeutic potential. Am J Trans Res 2010, 2:65-74.
28. Feldman D.E., Chauhan V., Koong A.C. The unfolded protein response: a novel component of the hypoxic stress response in tumors. Mol Cancer Res 2005, 3:597-605.
29. Clarke C., Smyth M.J. Calreticulin exposure increases cancer immunogenicity. Nat Biotechnol 2007, 25:192-193.
30. Hong S.H., Misek D.E., Wang H., Puravs E., Giordano T.J., Greenson J.K., et al. An autoantibody-mediated immune response to calreticulin isoforms in pancreatic cancer. Cancer Res 2004, 64:5504-5510.
31. Yoshio T., Morita T., Kimura Y., Tsujii M., Hayashi N., Sobue K. Caldesmon suppresses cancer cell invasion by regulating podosome/invadopodium formation. FEBS Lett 2007, 581:3777-3782.
32. Chakrabarty S., Kondratick L. Insulin-like growth factor binding protein-2 stimulates proliferation and activates multiple cascades of the mitogen-activated protein kinase pathways in NIH-OVCAR3 human epithelial ovarian cancer cells. Cancer Biol Ther 2006, 5:189-197.
33. Lee E.J., Mircean C., Shmulevich I., Wang H., Liu J., Niemisto A., et al. Insulin-like growth factor binding protein 2 promotes ovarian cancer cell invasion. Mol Cancer 2005, 4:7.
34. Wang H., Rosen D.G., Wang H., Fuller G.N., Zhang W., Liu J. Insulin-like growth factor-binding protein 2 and 5 are differentially regulated in ovarian cancer of different histologic types. Mod Pathol 2006, 19:1149-1156.
35. Ruan W.J., Lin J., Xu E.P., Xu F.Y., Ma Y., Deng H., et al. IGFBP7 plays a potential tumor suppressor role against colorectal carcinogenesis with its expression associated with DNA hypomethylation of exon 1. J Zhejiang Univ Sci B 2006, 7:929-932.
36. Landberg G., Ostlund H., Nielsen N.H., Roos G., Emdin S., Burger A.M., et al. Downregulation of the potential suppressor gene IGFBP-rP1 in human breast cancer is associated with inactivation of the retinoblastoma protein, cyclin E overexpression and increased proliferation in estrogen receptor negative tumors. Oncogene 2001, 20:3497-3505.
37. Mutaguchi K., Yasumoto H., Mita K., Matsubara A., Shiina H., Igawa M., et al. Restoration of insulin-like growth factor binding protein-related protein 1 has a tumor-suppressive activity through induction of apoptosis in human prostate cancer. Cancer Res 2003, 63:7717-7723.
38. Cheung L.W., Au S.C., Cheung A.N., Ngan H.Y., Tombran-Tink J., Auersperg N., et al. Pigment epithelium-derived factor is estrogen sensitive and inhibits the growth of human ovarian cancer and ovarian surface epithelial cells. Endocrinology 2006, 147:4179-4191.
39. Paz A., Haklai R., Elad-Sfadia G., Ballan E., Kloog Y. Galectin-1 binds oncogenic H-Ras to mediate Ras membrane anchorage and cell transformation. Oncogene 2001, 20:7486-7493.
40. Rabinovich G.A. Galectin-1 as a potential cancer target. Br J Cancer 2005, 92:1188-1192.
41. Visintin I., Feng Z., Longton G., Ward D.C., Alvero A.B., Lai Y., et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res 2008, 14:1065-1072.
42. Umezu T., Yamanouchi H., Iida Y., Miura M., Tomooka Y. Follistatin-like-1, a diffusible mesenchymal factor determines the fate of epithelium. Proc Natl Acad Sci USA 2010, 107:4601-4606.
43. Chan Q.K., Ngan H.Y., Ip P.P., Liu V.W., Xue W.C., Cheung A.N. Tumor suppressor effect of follistatin-like 1 in ovarian and endometrial carcinogenesis: a differential expression and functional analysis. Carcinogenesis 2009, 30:114-121.
44. Mashimo J., Maniwa R., Sugino H., Nose K. Decrease in the expression of a novel TGF beta1-inducible and ras-recision gene, TSC-36, in human cancer cells. Cancer Lett 1997, 113:213-219.
45. Gery S., Yin D., Xie D., Black K.L., Koeffler H.P. TMEFF1 and brain tumors. Oncogene 2003, 22:2723-2727.
46. Gill J.H., Kirwan I.G., Seargent J.M., Martin S.W., Tijani S., Anikin V.A., et al. MMP-10 is overexpressed, proteolytically active, and a potential target for therapeutic intervention in human lung carcinomas. Neoplasia 2004, 6:777-785. (New York, NY.
47. Seargent J.M., Loadman P.M., Martin S.W., Naylor B., Bibby M.C., Gill J.H. Expression of matrix metalloproteinase-10 in human bladder transitional cell carcinoma. Urology 2005, 65:815-820.
48. Miyata Y., Iwata T., Maruta S., Kanda S., Nishikido M., Koga S., et al. Expression of matrix metalloproteinase-10 in renal cell carcinoma and its prognostic role. Eur Urol 2007, 52:791-797.
49. Lopez-Otin C., Matrisian L.M. Emerging roles of proteases in tumour suppression. Nat Rev 2007, 7:800-808.